Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Product sales	$ 8,118	$ 2,009	$ 23,798	$ 6,221
Product royalty revenues	1,409	1,065	3,682	2,393
Research and development reimbursements	532	497	799	501
Contract revenues	1,194		21,194	2,500
Total Revenues:	11,253	3,571	49,473	11,615
Cost of sales	4,445	2,314	14,261	8,958
Expenses:
Research and development	1,986	4,402	6,246	13,786
Selling, general and administrative	14,867	12,054	44,094	37,606
Total Expenses:	16,853	16,456	50,340	51,392
Loss from operations	(10,045)	(15,199)	(15,128)	(48,735)
Interest expense	(1,893)	(786)	(6,657)	(2,477)
Derivative gain		14		36
Other expense, net	(13)	(6)	(28)	(20)
Bargain purchase gain			27,336
(Loss) income before income taxes	(11,951)	(15,977)	5,523	(51,196)
Income tax benefit			15,972
Net (loss) income attributable to common stockholders	$ (11,951)	$ (15,977)	$ 21,495	$ (51,196)
Basic
Basic (loss) income per share:	$ (0.21)	$ (0.30)	$ 0.39	$ (0.96)
Weighted average common stock shares outstanding:	55,604,708	53,767,099	55,170,569	53,531,770
Diluted
Diluted (loss) income per share:	$ (0.21)	$ (0.30)	$ 0.38	$ (0.96)
Diluted weighted average common stock shares outstanding:	55,604,708	53,767,099	56,204,358	53,531,770